AstraZeneca Results Presentation Deck
What's next in Rare Disease
Advancing diversified pipeline
33
What's next
Selected Phase I/II new medicines
ALXN1720
(3rd-generation C5)
gMG
ALXN2040
(Factor D)
geographic atrophy
ALXN1820
(anti-properdin)
haematology
ALXN1830
(anti-FcRn)
gMG, WAIHA
ALXN2050
(Factor D)
PNH, gMG, renal indications
ALXN1850
(next-generation asfotase alfa) New in
hypophosphatasia Phase 1 ✓
What's now
Phase III new medicines
ALXN1840
Wilson disease
acoramidis (ALXN2060)
ATTR
WAIHA = warm autoimmune haemolytic anaemia; FcRn = neonatal Fc receptor for immunoglobulin G; ATTR= amyloid transthyretin amyloidosis; EVH = extravascular haemolysis. 1. Japan-only trial.
Major Phase III lifecycle management
Soliris
Guillain-Barré syndrome¹
CAEL-101
AL-amyloidosis
danicopan (ALXN2040)
PNH w/EVH
Ultomiris
New in
Phase III
multiple indicationsView entire presentation